European Journal of Medicinal Chemistry p. 417 - 428 (2012)
Update date:2022-08-05
Topics:
Milelli, Andrea
Tumiatti, Vincenzo
Micco, Marialuisa
Rosini, Michela
Zuccari, Guendalina
Raffaghello, Lizzia
Bianchi, Giovanna
Pistoia, Vito
Fernando Díaz
Pera, Benet
Trigili, Chiara
Barasoain, Isabel
Musetti, Caterina
Toniolo, Marianna
Sissi, Claudia
Alcaro, Stefano
Moraca, Federica
Zini, Maddalena
Stefanelli, Claudio
Minarini, Anna
Novel 1,4,5,8-naphthalenetetracarboxylic diimide (NDI) derivatives were synthesized and evaluated for their antiproliferative activity on a wide number of different tumor cell lines. The prototypes of the present series were derivatives 1 and 2 characterized by interesting biological profiles as anticancer agents. The present investigation expands on the study of structure-activity relationships of prototypes 1 and 2, namely, the influence of the different substituents of the phenyl rings on the biological activity. Derivatives 3-22, characterized by a different substituent on the aromatic rings and/or a different chain length varying from two to three carbon units, were synthesized and evaluated for their cytostatic and cytotoxic activities. The most interesting compound was 20, characterized by a linker of three methylene units and a 2,3,4-trimethoxy substituent on the two aromatic rings. It displayed antiproliferative activity in the submicromolar range, especially against some different cell lines, the ability to inhibit Taq polymerase and telomerase, to trigger caspase activation by a possible oxidative mechanism, to downregulate ERK 2 protein and to inhibit ERKs phosphorylation, without acting directly on microtubules and tubuline. Its theoretical recognition against duplex and quadruplex DNA structures have been compared to experimental thermodynamic measurements and by molecular modeling investigation leading to putative binding modes. Taken together these findings contribute to define this compound as potential Multitarget-Directed Ligands interacting simultaneously with different biological targets.
View MoreShenzhen HwaGen Pharmaceutical Co., Ltd
website:http://www.rafflespt.com
Contact:+86-752-5538396
Address:Guangdong Huizhou China
Shuanghe Bio-Technology Limited(expird)
Contact:+86-571-61710758,18968016640
Address:Jinqiao north road 916# Fuyang
Shanghai better-in Medical Technology Co.,LTD.
Contact:+86-21-38921049
Address:Lane 720 zhangjianggaoke cailun road, Pudong, Shanghai, room 513
Contact:86-28-61993785
Address:No.70-13-21, North Section, Erhuan
Ningbo Inno Pharmchem Co., Ltd.
Contact:86-574-87319282
Address:6F-5,NO.163 RUIQING RD.,NINGBO 315000 CHINA
Doi:10.1016/S0040-4039(01)81052-2
(1987)Doi:10.1134/S1070328408090054
(2008)Doi:10.1039/b818853j
(2009)Doi:10.1007/s11172-015-0879-5
(2015)Doi:10.1021/jo5014542
(2014)Doi:10.1007/s11172-008-0096-6
(2008)